Sale!

CA 27.29 Breast Cancer Marker Test

Original price was: $450.Current price is: $300.

-33%

The CA 27.29 Breast Cancer Marker Test is a sophisticated blood-based immunoassay that measures the levels of CA 27.29 antigen, a specific tumor marker primarily associated with breast cancer. This advanced diagnostic tool plays a crucial role in detecting breast cancer recurrence, monitoring treatment effectiveness, and assessing disease progression. The test is particularly valuable for patients with a history of breast cancer, those undergoing treatment, or individuals with suspicious symptoms. By providing quantitative measurements of this specific biomarker, healthcare providers can make more informed decisions about treatment strategies and follow-up care. The test costs $300 USD and offers significant benefits including early detection capabilities, treatment monitoring precision, and personalized cancer management insights. With rapid turnaround times and nationwide availability, this test represents a critical component of comprehensive breast cancer care and surveillance programs.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

CA 27.29 Breast Cancer Marker Test – Advanced Cancer Detection & Monitoring

Understanding the CA 27.29 Breast Cancer Marker Test

The CA 27.29 Breast Cancer Marker Test represents a cutting-edge diagnostic advancement in oncology, specifically designed to detect and monitor breast cancer through sophisticated biomarker analysis. This specialized blood test measures the levels of CA 27.29 antigen, a mucin glycoprotein that serves as a reliable indicator of breast cancer activity within the body. As one of the most specific tumor markers available for breast cancer management, this test provides invaluable insights that help guide treatment decisions and monitor disease progression with exceptional precision.

What Does the CA 27.29 Test Measure?

The CA 27.29 test specifically detects and quantifies the presence of the CA 27.29 antigen, which is produced by breast cancer cells. This biomarker serves multiple critical functions in cancer management:

  • Detection of cancer recurrence in patients with previous breast cancer diagnoses
  • Monitoring treatment response during chemotherapy, radiation, or targeted therapies
  • Assessment of disease progression and metastatic spread
  • Evaluation of treatment effectiveness and potential need for therapy adjustments
  • Providing prognostic information about cancer behavior and potential outcomes

Who Should Consider This Test?

The CA 27.29 Breast Cancer Marker Test is recommended for specific patient populations who can benefit most from this advanced diagnostic tool:

Primary Candidates Include:

  • Patients with a history of breast cancer for routine monitoring and recurrence detection
  • Individuals currently undergoing breast cancer treatment to assess therapy effectiveness
  • Patients experiencing symptoms suggestive of breast cancer recurrence
  • Women with suspicious breast lumps, changes in breast tissue, or abnormal mammogram results
  • Individuals with family history of breast cancer seeking comprehensive screening
  • Patients with metastatic breast cancer requiring ongoing disease monitoring

Symptoms That May Warrant Testing:

  • New or changing breast lumps or masses
  • Unexplained weight loss or fatigue
  • Persistent bone pain or discomfort
  • Changes in breast appearance or texture
  • Nipple discharge or skin changes
  • Swelling in lymph nodes or surrounding tissues

Comprehensive Benefits of CA 27.29 Testing

Choosing the CA 27.29 Breast Cancer Marker Test provides numerous advantages for comprehensive cancer care and management:

Early Detection Capabilities

This test can detect rising CA 27.29 levels before physical symptoms or imaging changes become apparent, allowing for earlier intervention and potentially better treatment outcomes.

Treatment Monitoring Precision

By tracking biomarker levels throughout treatment, healthcare providers can objectively assess therapy effectiveness and make timely adjustments to treatment plans when necessary.

Personalized Cancer Management

The quantitative nature of this test enables personalized treatment approaches based on individual biomarker response patterns, leading to more targeted and effective care strategies.

Peace of Mind and Proactive Health Management

Regular monitoring provides reassurance for patients and enables proactive management of their health journey with objective data to guide decisions.

Understanding Your Test Results

Interpreting CA 27.29 test results requires professional medical expertise, but understanding the general principles can help patients participate more actively in their care:

Normal Range Interpretation

Normal CA 27.29 levels typically fall below 38 U/mL, though reference ranges may vary slightly between laboratories. Consistently normal results generally indicate stable disease or effective treatment control.

Elevated Levels and Clinical Significance

Elevated CA 27.29 levels may suggest active cancer presence, disease progression, or treatment resistance. However, elevated levels alone don’t confirm cancer diagnosis and must be interpreted alongside clinical findings and imaging studies.

Trend Analysis Importance

The pattern of CA 27.29 levels over time often provides more valuable information than single measurements. Rising trends may indicate disease progression, while declining trends typically suggest positive treatment response.

Integration with Comprehensive Assessment

CA 27.29 results should always be evaluated in conjunction with physical examinations, imaging studies, and other clinical findings to form a complete clinical picture.

Test Pricing and Availability

Price Type Amount (USD)
Discount Price $300
Regular Price $450

Nationwide Accessibility

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our extensive network ensures that advanced breast cancer testing is accessible to patients nationwide.

Sample Requirements and Processing

The test requires 2 mL (minimum 0.5 mL) of serum collected in one SST tube. Samples must be shipped refrigerated or frozen, and a brief clinical history along with the duly filled Test Send Out Consent Form (Form 35) is mandatory for processing.

Turnaround Time

For optimal processing, samples should be submitted by the 7th of each month. Results are typically available within 2-3 weeks, providing timely information to guide clinical decisions.

Take Control of Your Breast Health Today

Early detection and proactive monitoring are crucial components of successful breast cancer management. The CA 27.29 Breast Cancer Marker Test provides the advanced diagnostic capabilities needed to stay ahead of this disease. Don’t wait for symptoms to appear – take proactive steps toward comprehensive breast health management.

Ready to schedule your test? Contact our dedicated healthcare team today at +1(267) 388-9828 or book your appointment online. Our experienced oncology specialists are available to answer your questions and guide you through the testing process with compassion and expertise.

Take the first step toward comprehensive breast cancer monitoring and management. Your health journey deserves the most advanced diagnostic tools available – choose the CA 27.29 Breast Cancer Marker Test for peace of mind and proactive health management.